AIRFLUSAL SPRAYHALER 25 mikrog / 250 mikrog / annos inhalaatiosumute, suspensio Soome - soome - Fimea (Suomen lääkevirasto)

airflusal sprayhaler 25 mikrog / 250 mikrog / annos inhalaatiosumute, suspensio

sandoz a/s sandoz a/s - salmeteroli xinafoas,fluticasoni propionas - inhalaatiosumute, suspensio - 25 mikrog / 250 mikrog / annos - salmeteroli ja flutikasoni

Iclusig Euroopa Liit - soome - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. katso kohdat 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Coagadex Euroopa Liit - soome - EMA (European Medicines Agency)

coagadex

bpl bioproducts laboratory gmbh - ihmisen hyytymistekijä x - faktorin x puute - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex on tarkoitettu verenvuototapahtumien hoitoon ja ennaltaehkäisyyn sekä perioperatiiviseen hoitoon potilailla, joilla on perinnöllinen tekijä x-puutos. coagadex on tarkoitettu kaikille ikäryhmille.

Pemazyre Euroopa Liit - soome - EMA (European Medicines Agency)

pemazyre

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastiset aineet - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Sefitude tabletti, päällystetty Soome - soome - Fimea (Suomen lääkevirasto)

sefitude tabletti, päällystetty

florealis ehf. - valerian root dry ethanol extract (3-6:1) - tabletti, päällystetty - valerianae radix

Pepelia enterokapseli, pehmeä Soome - soome - Fimea (Suomen lääkevirasto)

pepelia enterokapseli, pehmeä

florealis ehf. - peppermint oil - enterokapseli, pehmeä - menthae piperitae aetheroleum

Minjuvi Euroopa Liit - soome - EMA (European Medicines Agency)

minjuvi

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Opzelura Euroopa Liit - soome - EMA (European Medicines Agency)

opzelura

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muut dermatologiset valmisteet - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

LINCOCIN 300 mg/ml injektioneste Soome - soome - Fimea (Suomen lääkevirasto)

lincocin 300 mg/ml injektioneste

pharmacia & upjohn limited - lincomycini hydrochloridum - injektioneste - 300 mg/ml - lidokaiini

LINCOCIN 500 mg kapseli Soome - soome - Fimea (Suomen lääkevirasto)

lincocin 500 mg kapseli

pfizer manufacturing belgium n.v. - lincomycini hydrochloridum monohydricum - kapseli - 500 mg - lidokaiini